
|Videos|October 27, 2017
Expected Findings of the SWOG S1505 Trial in Pancreatic Cancer
Author(s)Davendra Sohal, MD, MPH
Davendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the SWOG S1505 trial, which is exploring perioperative mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
How the Immune System Drives Nerve Growth in TNBC
3
AMH Testing Predicts Chemotherapy Benefit in RxPONDER Breast Cancer
4
FAQ: When and How to Discontinue Lenalidomide Maintenance in Multiple Myeloma
5



































